Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

Anouk K. M. Claessens, Frans L. G. Erdkamp, Marta Lopez-Yurda, Jeanette M. Bouma, Jeany M. Rademaker-Lakhai, Aafke H. Honkoop, Hiltje de Graaf, Vivianne C. G. Tjan-Heijnen, Monique E. M. M. Bos*, Dutch Breast Canc Res Grp BOOG

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)713-722
Number of pages10
JournalActa Oncologica
Volume59
Issue number6
DOIs
Publication statusPublished - 2 Jun 2020

Keywords

  • METRONOMIC CHEMOTHERAPY
  • 1ST-LINE TREATMENT
  • CLINICAL-OUTCOMES
  • TREATMENT PATTERNS
  • OPEN-LABEL
  • CYCLOPHOSPHAMIDE
  • CAPECITABINE
  • BENEFIT
  • BEVACIZUMAB
  • SURVIVAL

Cite this

Claessens, A. K. M., Erdkamp, F. L. G., Lopez-Yurda, M., Bouma, J. M., Rademaker-Lakhai, J. M., Honkoop, A. H., de Graaf, H., Tjan-Heijnen, V. C. G., Bos, M. E. M. M., & Dutch Breast Canc Res Grp BOOG (2020). Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. Acta Oncologica, 59(6), 713-722. https://doi.org/10.1080/0284186X.2020.1731923